New Hope for Knee Osteoarthritis Patients as Contura’s Arthrosamid® Enters Canadian Market

Mississauga, Ontario – March 6, 2025 – Contura Orthopedics (Canada) Ltd, a leading provider of hydrogel-based products, announced today that NeuPath Centre for Pain & Spine in Mississauga, Ontario has performed the first injection of Arthrosamid® in North America.  Prior to Health Canada’s approval of Arthrosamid®, patients would travel to Europe to access this innovative hydrogel that provides up to four years of pain relief for knee osteoarthritis sufferers.¹

“At NeuPath our mission is to improve the lives of Canadians living with chronic pain and we are proud to provide our patients with access to this latest innovation in pain therapy, reinforcing our commitment to delivering safe, effective, patient-centred care,” said Dr. James Kim, Medical Director, NeuPath Centre for Pain & Spine. 

Over four million Canadians live with osteoarthritis, with knee osteoarthritis being a leading cause of pain, mobility issues, and reduced quality of life.  Conventional non-surgical solutions like painkillers and corticosteroid injections provide only temporary relief.   That’s why Dr. Julie Letosky, who administered over 100 injections in her veterinary practice and observed its incredible results, was eager to experience the benefits of Arthrosamid® for her own painful osteoarthritic knees when it became available in Canada.

“I have been using ArthramidVet® for a year for canine joints and have seen remarkable improvement in my patients,” said Dr. Letosky. “Knowing intimately how this particular hydrogel works to address the synovial inflammation in the joint became very interesting to me as I began the struggle with my own knees.”

Arthrosamid® (2.5% iPAAG) is a unique non-biodegradable hydrogel injection. Unlike traditional OA injections, Arthrosamid® integrates into the synovial tissue of the knee, helping to cushion the joint and reduce pain with a single-dose. 

“Contura’s mission was to develop something with the same physical properties as soft tissue that can provide long lasting structural support,” said Peter Tomashewski, commercial country leader for Contura Orthopedics (Canada) Ltd. I look forward to collaborating with other NeuPath Centre for Pain & Spine locations and the broader healthcare community to expand access to this groundbreaking, long-lasting pain relief option in Canada."

About Contura

Contura Orthopedics (Canada) Ltd. is based in Mississauga, Ontario. It is a subsidiary of the UK-based Contura Group, which has its manufacturing facility in Denmark. Contura develops and manufactures innovative medical products in the fields of women’s health, orthopedics and animal health using its unique, patented hydrogel technology. Its hydrogel-based products are non-particulate and biocompatible, allowing for its non-absorbable, non-migratory and highly durable properties. For more information, visit www.contura.com.

^References:

^{1.Bliddal, H., et al. (2024) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 4 Years After Treatment. Presented at EORS 2024.}